JATT III Acquisition Corp Closes $69 Million IPO to Target Healthcare Sector

JATT III Acquisition Corp, a special purpose acquisition company (SPAC), has closed its initial public offering, raising $69 million in gross proceeds. The company's shares began trading on the Nasdaq Global Market on August 26, 2026, under the ticker symbol JTTT.

IPO Details

The offering consisted of 6,900,000 ordinary shares priced at $10.00 per share, according to a company press release. The total amount raised includes the full exercise of the underwriters' over-allotment option, which added 900,000 shares to the offering. The IPO officially closed on August 27, 2026.

The U.S. Securities and Exchange Commission had declared the company's registration statement effective on August 25, 2026. Guggenheim Securities, LLC acted as the sole book-running manager for the offering.

Company Strategy and Focus

Ad

JATT III Acquisition Corp is a blank check company, a publicly traded firm created solely to merge with or acquire a private company, thereby taking it public. The Cayman Islands-incorporated entity has stated its focus is on identifying a target in the healthcare sector, with a specific emphasis on biotechnology and life sciences.

As is typical for a SPAC at this stage, JATT III has not yet identified a specific business combination target. The capital raised from the IPO will be held in a trust account to fund a future acquisition.

Key Investors

A number of institutional investors participated in the offering, including RA Capital Management, Janus Henderson Investors, and Adage Capital Partners, L.P. Additionally, AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. have indicated non-binding interest in participating in a private placement that may occur alongside the company's eventual business combination.